Genetic platform called mRNA (messenger RNA) for development of vaccine for COVID-19
Vaccine development using a genetic platform called mRNA (messenger RNA) is in progress.
Currently, no approved vaccines exist to prevent infection.
The investigational vaccine,developed by using a genetic platform called mRNA directs the body’s cells to express a virus protein that it is hoped will elicit a robust immune response.Prior studies of related Coronaviruses that cause severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) helped to quickly develop mRNA-1273. The vaccine is called mRNA-1273.
Coronaviruses are spherical and have spikes protruding from their surface, giving the particles a crown-like appearance. The spike binds to human cells, allowing the virus to gain entry. Once the genetic information became available, it was very quick to select a sequence to express the stabilized spike protein of the virus in the existing mRNA platform.
Support was raised for the manufacturing of the vaccine candidate for the Phase 1 clinical trial.
Finding a safe and effective vaccine to prevent infection with COVID-19 is an urgent public health priority. Phase 1 clinical trial, launched in record speed, is an important first step toward achieving that goal.
The study is evaluating different doses of the experimental vaccine for safety and its ability to induce an immune response in participants. This is the first of multiple steps in the clinical trial process for evaluating the potential benefit of the vaccine.
Rapid acceleration of manufacturing capabilities that could allow for the future manufacture of millions of doses should mRNA-1273 prove to be safe and of expected benefit has already started. Work around-the-clock to make sure a vaccine is available as quickly and as broadly as possible is in progress to enable the best chance for success.
The virus that causes COVID-19, can cause a mild to severe respiratory illness and include symptoms of fever, cough and shortness of breath. COVID-19 cases were first identified in December 2019 in Wuhan, Hubei Province, China.
Countries are ramping up its battle (such as providing oxygen supply and ventilation equipment) against the Coronavirus outbreak, shutting down social life and ordering the most vulnerable to isolate themselves for specified time.The government has been encouraging people to work from home to ensure they don’t fall prey to Covid-19. Many bus crews and private operators, for example donot have that luxury and not providing them safety kits like hand sanitisers and mask have made many drivers, conductors and their families worried. more
Currently, no approved vaccines exist to prevent infection.
The investigational vaccine,developed by using a genetic platform called mRNA directs the body’s cells to express a virus protein that it is hoped will elicit a robust immune response.Prior studies of related Coronaviruses that cause severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) helped to quickly develop mRNA-1273. The vaccine is called mRNA-1273.
Coronaviruses are spherical and have spikes protruding from their surface, giving the particles a crown-like appearance. The spike binds to human cells, allowing the virus to gain entry. Once the genetic information became available, it was very quick to select a sequence to express the stabilized spike protein of the virus in the existing mRNA platform.
Support was raised for the manufacturing of the vaccine candidate for the Phase 1 clinical trial.
Finding a safe and effective vaccine to prevent infection with COVID-19 is an urgent public health priority. Phase 1 clinical trial, launched in record speed, is an important first step toward achieving that goal.
The study is evaluating different doses of the experimental vaccine for safety and its ability to induce an immune response in participants. This is the first of multiple steps in the clinical trial process for evaluating the potential benefit of the vaccine.
Rapid acceleration of manufacturing capabilities that could allow for the future manufacture of millions of doses should mRNA-1273 prove to be safe and of expected benefit has already started. Work around-the-clock to make sure a vaccine is available as quickly and as broadly as possible is in progress to enable the best chance for success.
The virus that causes COVID-19, can cause a mild to severe respiratory illness and include symptoms of fever, cough and shortness of breath. COVID-19 cases were first identified in December 2019 in Wuhan, Hubei Province, China.
Countries are ramping up its battle (such as providing oxygen supply and ventilation equipment) against the Coronavirus outbreak, shutting down social life and ordering the most vulnerable to isolate themselves for specified time.The government has been encouraging people to work from home to ensure they don’t fall prey to Covid-19. Many bus crews and private operators, for example donot have that luxury and not providing them safety kits like hand sanitisers and mask have made many drivers, conductors and their families worried. more
Viewed by 26
Antibiotics have seen a fate of invoking the genesis of new virulent strains of bacteria as seen with tuberculosis. Although virus is different, but through mutation the results, i.e. causality, insofar as the viruses becoming hardier, causing influenza or common cold, to name just a few. Therein lies similarity between these microbes, that we need to be aware of. more
Nov 29
To curb the rising numbers of COVID cases is important - many areas are in the clutches of a second wave of infection and possibly subsequent waves may follow. A more complete picture of both the efficacy and safety profile of vaccine candidates are important, that gives the confidence in their potential. The fight against COVID-19 continues to rage. The swift approval of the potential vaccine candidates will spark a fast roll-out of the first batches that will likely be provided to front-line healthcare workers. The conditional recommendation against the use of remdesivir by WHO in hospitalized patients, regardless of the severity of the disease is disappointing.The global health organization said there is currently no evidence that remdesivir improves survival and other outcomes in these patients.WHO is in support of continued enrollment in trials evaluating remdesivir. However Gilead Sciences downplayed the WHO recommendations and said its antiviral is recognized as a “standard of care" for the treatment of hospitalized patients with COVID-19. Remdesivir has demonstrated its clinical benefits in multiple studies, the company said.The WHO guidelines appear to ignore this evidence at a time when cases are dramatically increasing around the world and doctors are relying on Veklury as the first and only approved antiviral treatment for patients with COVID-19 in approximately , say around 50 countries. Its not that capabilities to deliver COVID-19 antibody treatments are not being ramped up. Its required to bolster the manufacturing of the antibody cocktail, such as REGN-COV2 that Roche developed in partnership with Regeneron. No matter what, irrespective of other therapeutics, the demand for antibody cocktails may far outstrip supply, so one needs to make sure the antibody cocktail targets really the right patient groups. more
Nov 23
The high-efficacy candidate vaccines against the coronavirus disease from Pfizer-BioNTech and Moderna represent triumphs of science, but researchers and officials say India is unlikely to get either product in the doses needed to address its pandemic. Both the Pfizer-BioNTech and Moderna vaccine candidates have in clinical trials shown 95 per cent efficacy in protecting people from Covid-19, emerging from an unprecedented pace of research that has brought vaccines in sight only 10 months since scientists unveiled the genome of SARS-CoV-2, the Covid-19 virus. Pfizer and BioNTech have announced they can produce 50 million doses in 2020 and up to 1.3 billion doses during 2021. Moderna has said it can ship 20 million doses in 2020 and 500 million to 1 billion during 2021. But health researchers and officials in India do not expect either of these vaccines to be available in the country in the quantities required to support mass vaccination campaigns — ground raised is that high-income nations have already made advance purchase orders. This ignores that vaccine manufacturing cannot be scaled up to meet the subsequent purchase orders. The Pfizer-BioNTech and Moderna candidates are both novel vaccines that use genetic material called RNA as a “platform” that promises certain advantages over traditional or other platforms. more
Nov 19
We are already a vaccinated nation, as only in the year 1978 was free mass vaccination stopped. Given the procedure of their manufacture, resource scarcity and that those above middle age are susceptible, with adolescents doing better with innate immunity, this should be taken with deliberation, in India at least. After all, virus mutates. Agree 100% that flu shots have given great benefit and many cases these vaccines could have prevented. Battles, one undertakes, therefore, he or she must selected carefully. more
Nov 18
